VTE and Anticoagulation – Guideline Updates for 2024
This 0.5-hour, Whiteboard Animation Webcast is designed to review the important current guidelines for VTE and anticoagulation. Primary care physicians, internists, family medicine physicians, allied healthcare professionals and other healthcare providers involved in the care of patients with VTE 
Geoffrey ...
View Course
- Discuss current guidelines for the anticoagulation management of VTE
Geoffrey ...View Course
Shared Decision-Making and Patient Education to Promote Adherence to DOACs and Continuity of Care in VTE
This 0.5-hour, Whiteboard Animation Webcast is designed to review collaboration with the multidisciplinary healthcare team and the patient to improve shared decision-making and promote adherence to DOACs for patients with VTE. Primary care physicians, internists, family medicine physicians, allied healthcare professionals and other healthcare providers involved in the care of patients with VTE
- Understand the role of patient education ...
View Course
Strategies to Coordinate the Multidisciplinary Team for Secondary Prevention, Long-Term Treatment, and the Assessment of Bleeding Risk
This 0.5-hour, Whiteboard Animation Webcast is designed to review collaboration with the multidisciplinary healthcare team for secondary prevention, long term treatment and bleeding risk assessment for patients with VTE. Primary care physicians, internists, family medicine physicians, allied healthcare professionals and other healthcare providers involved in the care of patients with VTE
- Develop strategies for collaboration with the multidisciplinary healthcare ...
View Course
Review of Clinical Trial and Real-World Data for DOAC and other Anticoagulation Therapeutics for VTE
This 0.5-hour, Whiteboard Animation Webcast is designed to review clinical trial and deal-world data for DOAC and other anticoagulation therapeutics for VTE. A majority of new diagnoses of VTE are made by primary care professionals. Evidence-based guidelines for the management of VTE include the most recent updates from the American Society of Hematology (ASH, 2020), the European Society of Cardiology ...
View Course
View Course
Optimizing Echocardiographic and CMR Assessment in the Diagnosis and Management of Hypertrophic Cardiomyopathy
This CME program, derived from content presented at the European Association of Cardiovascular Imaging Annual Congress EACVI 2023 in Barcelona, Spain, will highlight how to optimize echocardiographic and CMR assessment in the diagnosis and management of hypertrophic cardiomyopathy. In hypertrophic cardiomyopathy, multimodality imaging is crucial to confirm diagnosis, assess for presence and mechanism of left ventricular outflow tract obstruction, and ...
View Course
Accurate and Effective Imaging in the Diagnosis and Management of Hypertrophic Cardiomyopathy: A Practical Approach
Accurate diagnosis is vital for the successful management of patients with HCM. Mistakes and delays in diagnosis are common. Hypertrophic cardiomyopathy commonly "masquerades" as asthma, anxiety, mitral prolapse, and coronary artery disease. However, once properly diagnosed, patients with HCM can be effectively managed to improve both symptoms and survival. Today, the diagnosis of HCM relies on the identification of increased ...
View Course
View Course
Specific Reversal of Anti-Factor Xa DOAC Anticoagulation: Incorporating Latest Data into Practice and Institutional Protocols
Severe and life-threatening hemorrhage in patients receiving anti-FXa DOACs is unusual; especially for the most-feared bleeding complication, ICH, events are significantly less common than for patients on vitamin K antagonists (VKA). Still, these events occur, and there is a need for specific, timely, evidence-guided, and multimodal management of DOAC-treated patients with hemorrhage to avoid worsening morbidity, excessive cost and length ...
View Course
View Course
Case Studies in Optimal Management of Anti-FXa-DOAC-Associated Intracranial Hemorrhage: Specific vs Nonspecific Anticoagulant Reversal
This CME program is derived from content presented at the 8th European Stroke Organization Conference (ESOC 2022). This educational activity, chaired by Dr. Thorsten Steiner, will review optimal management strategies of patients with anti-FXa-DOAC-associate Intracranial Hemorrhage (ICH). The worldwide utilization of DOACs for a number of different indications has continuously increased over the past decade, and while the anti-FXa DOACS ...
View Course
View Course
The Impact of the COVID Pandemic on Continuity of Care and Adherence to DAPT Among Patients with CAD/ACS/PCI
Areas of North America and Western Europe have struggled with repeated waves and emerging variants of SARS CoV-2 infection. Even as some countries and regions strive to return to pre-pandemic behavior, the COVID-19 pandemic continues to exert many deleterious effects on the delivery of continuing healthcare for many vulnerable populations. Those affected include patients who would be expected to benefit ...
View Course
View Course
Optimal Guideline Directed Medical Therapy for Heart Failure
This CME/CE program will highlight optimal guideline directed medical therapy for patients with heart failure (HF). The expert faculty will first review current ACC/AHA and ESC recommendations for directed medical therapy to treat patients with heart failure with reduced ejection fraction (HFrEF). Following, the faculty will analyze clinical trial data for SGLT2is, vericiguat, and omecamtiv mecarbil therapeutics. Next, clinical strategies ...
View Course
View Course
